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ABSTRACT
CpG methylation is a key component of the
epigenome architecture that is associated with
changes in gene expression without a change to
the DNA sequence. Since the first reports on
deregulation of DNA methylation, in diseases such
as cancer, and the initiation of the Human
Epigenome Project, an increasing need has arisen
for a detailed, high-throughput and quantitative
method of analysis to discover and validate normal
and aberrant DNA methylation profiles in large
sample cohorts. Here we present an improved
protocol using base-specific fragmentation and
MALDI-TOF mass spectrometry that enables a
sensitive and high-throughput method of DNA
methylation analysis, quantitative to 5% methylation
for each informative CpG residue. We have deter-
mined the accuracy, variability and sensitivity of the
protocol, implemented critical improvements in
experimental design and interpretation of the data
and developed a new formula to accurately measure
CpG methylation. Key innovations now permit
determination of differential and allele-specific
methylation, such as in cancer and imprinting.
The new protocol is ideally suitable for detailed
DNA methylation analysis of multiple genomic
regions and large sample cohorts that is critical
for comprehensive profiling of normal and diseased
human epigenomes.
INTRODUCTION
DNA methylation is an epigenetic modiﬁcation of the
genome, whereby a methyl group is covalently linked
at position 5 of the cytosine pyrimidine ring (5-MeC),
typically occurring in a 50-CpG-30dinucleotide context.
These CpG sites are often concentrated in distinct areas
of the genome called CpG islands (1). The DNA
methylation state of CpG site(s) can aﬀect the chromatin
structure and transcriptional activity of the associated
gene. In the past decade, it has become apparent that
alterations in DNA methylation are not only linked to
normal developmental processes, but also to many human
diseases including cancer (2–8). Other human diseases
with aberrant DNA methylation include the Beckwith–
Wiedemann syndrome, the Prader–Willi syndrome and
the Angelman syndrome, in which the mono-allelic
methylation status (paternal or maternal) of a speciﬁc
genomic region has been lost, also known as loss of
imprinting (9). To unravel the mechanisms underlying
these developmental and pathological changes in DNA
methylation, an increasing need has arisen for an accurate
and quantitative method for analysis. Moreover, the
initiation of the Human Epigenome Project (HEP) has
also highlighted the need for a high-throughput, high
resolution and truly quantitative methods for DNA
methylation proﬁling (10–13).
Many technologies have been developed for evaluating
DNA methylation, reviewed in (14–18), but accurate and
reproducible quantiﬁcation of DNA methylation remains
challenging and only a small subset of techniques is
suitable for high-throughput applications and allele-
speciﬁc methylation analysis. The ‘gold-standard’ for
determining and quantifying the methylation state of a
genomic region at single-nucleotide resolution is by
sequence analysis after bisulphite conversion (19).
This method relies on the ability of sodium bisulphite to
eﬃciently deaminate cytosine residues to uracil in single-
stranded DNA, under conditions where 5-MeC remains
nonreactive. After PCR ampliﬁcation all uracil and
thymine residues have been ampliﬁed as thymine (T) and
only 5-MeC residues have been ampliﬁed as cytosine (C).
Subsequent sequencing of cloned PCR products gives
detailed information on every CpG site in the ampliﬁed
region. The main drawback is that clonal sequencing is
costly and time consuming and depending on the
heterogeneity of DNA methylation a large number of
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accurate representation of the DNA methylation proﬁle.
A novel approach for high-throughput DNA methyla-
tion based on MALDI-TOF mass spectrometry has been
recently introduced (20–22). This method is based on a
base-speciﬁc cleavage reaction combined with mass spec-
trometric analysis (MassCLEAVE
TM; Figure 1a). In brief,
the method employs a T7-promoter-tagged PCR ampliﬁ-
cation of bisulphite-converted DNA, followed by genera-
tion of a single-stranded RNA molecule and subsequent
base-speciﬁc cleavage (30 to either rUTP or rCTP) by
RNase A. The mixture of cleavage products diﬀering in
length and mass are analyzed by MALDI-TOF-MS.
Diﬀerences in template DNA methylation proﬁle will
result in changes in nucleotide sequence after bisulphite
treatment, which in turn will yield diﬀerent fragment
masses in the assay. The abundance of each fragment
(signal/noise level in the spectrum) is indicative of the
amount of DNA methylation in the interrogated sequence.
In this article, we critically evaluate the accuracy,
precision and sensitivity of the individual steps of the
MassCLEAVE
TM assay, address the success rate, deter-
mine its limitations and further improve the assay.
We also compare CpG methylation quantitation obtained
from mass spectrometry with clonal bisulphite sequencing
methylation analysis. Based on our new ﬁndings, we
demonstrate novel assays for: (i) allele-speciﬁc DNA
methylation, (ii) extracting known and novel single-
nucleotide polymorphism (SNP) data, and (iii) determin-
ing allelic-speciﬁc SNP-associated methylation levels.
MATERIALS AND METHODS
Insilico fragmentationanalysis foroptimal assaydesign
In the Supplementary Data, we detail how an in silico
fragmentation analysis (T-cleavage) can be performed on
the target sequence for DNA methylation analysis using
either the R-script (http://www.garvan.org.au/research/
research-groups/epigenetics.html) ‘Amplicon Report
Function’ (ARF) accompanying this article, or by
manual calculation.
Calculation ofDNA methylation state
The formula the MassCLEAVE
TM software uses to calcu-
late the DNA methylation level of fragments is as follows:
Methylation of fragment with n CpG sites
¼
SNR1 þ SNR2 þ ...þ SNRn
SNRNOME þ SNR1 þ SNR2 þ ...þ SNRn
where SNR is the signal-to-noise ratio of either the
unmethylated peak (NOME) or one of the methylated
peaks (1, 2,...,n) associated with this fragment. It is
important to note that the number associated with the
methylated peaks does not denote a particular CpG site,
but rather corresponds to the number of CpG sites
methylated within the fragment (with n being all CpG
sites of the fragment methylated). Therefore this formula
produces biases when comparing fragments with diﬀerent
numbers of CpG sites. For a fragment with a single CpG
site, theformula estimates theproportion of methylation at
that one site. For fragments with more than one CpG site
the formula estimates the proportion of fragments contain-
ing one or more methylated site(s). Therefore, fragments
with higher numbers of CpG sites will tend to be biased
towards higher ‘methylation levels’ as they have more
chances of containing one or more methylated sites.
We have derived a new measure of methylation that is
not biased by the number of sites within the fragment, and
incorporates the average methylation of each CpG site
within a fragment. To calculate the average methylation
level, we weight each SNR by the number of methylated
CpG sites represented in that peak using the following new
formula:
Average methylation of fragment with n CpG sites
¼
ð1=nÞSNR1 þð 2=nÞSNR2 þ ...þð n=nÞSNRn
SNRNOME þ SNR1 þ SNR2 þ ...þ SNRn
The R-script ‘Analyze Sequenom Function’ (ASF) accom-
panying this article, performs these calculations auto-
matically. All the DNA methylation levels presented in
this article have been recalculated based on this new
formula.
Samples
Sample collection and genomic DNA isolation has been
described in detail previously (23). Brieﬂy, fresh-frozen
tissue samples were collected from colorectal carcinomas
as well as matched adjacent normal colonic mucosa,
and DNA extractions were performed using the TRIZOL
reagent (Invitrogen). Enzymatically methylated (SssI
treated) gDNA (Chemicon International) and blood
gDNA (Roche human gDNA) were obtained
commercially.
Bisulphite-converted clones forprecision and accuracy
measurements
Previously bisulphite-converted, PCR-ampliﬁed, cloned
(pGEM-T Easy Vector, Promega) and sequence-veriﬁed
constructs were used as starting material for purely
methylated or unmethylated sequences (23). These con-
structs were generated for all three amplicons interrogated
(the CpG islands of EN1, SCTR and INHBB), and the
target sequences were again PCR ampliﬁed separately for
both methylated and unmethylated products, using the
primers and conditions as depicted in Supplementary
Table 1. The PCR products were analyzed via agarose
gel electrophoresis and the concentration was determined
using the BioAnalyzer 2100 (Agilent). Known ratios of
completely methylated and unmethylated PCR product
(0, 5, 10, 25, 50, 75, 90, 95 and 100% methylation)
were mixed and either analyzed immediately in a T7
transcription-RNase A digestion reaction, followed by a
MALDI-TOF-MS analysis (referred to as direct analysis),
or analyzed following an extra PCR step (referred
to as PCR+analysis). For the in silico analysis of the
20 tumor suppressor genes, described in Supplementary
Table 2, we designed primers and target regions using
MethPrimer (24).
e119 Nucleic Acids Research, 2007, Vol. 35, No. 18 PAGE2 OF14Figure 1. MALDI-TOF-MS DNA methylation analysis. Overview of the MassCLEAVE
TM assay. (A) Genomic DNA is bisulphite treated and PCR-
tagged to include the T7 promoter sequence. As shown, either top or bottom strand can be used for ampliﬁcation. Subsequent alkaline phosphatase (SAP)
treatment, in vitro transcription using T7R&DNA polymerase and a speciﬁc nucleotide mixture plus RNase A cleavage results in speciﬁc fragmentation.
As exempliﬁed, the top and bottom strands can have markedly diﬀerent fragmentation patterns. The obtained mixture of fragments can be analyzed by
MALDI-TOF-MS. Spectrum peaks representing methylated and unmethylated fragments are used to calculate methylation levels for every fragment.
(B) In silico transcript fragmentation. The use of T- or C-cleavage mixtures on either the top or bottom strand of bisulphite-treated DNA can yield quite
diﬀerentfragmentationpatterns.Here,thefragmentationoftheCpGislandofINHBB(chr2:119,998,230-119,998,596)isshown.CpGsitesarerepresented
by circles; white circle: methylation call will be obtained in the MassCLEAVE
TM assay; crossed gray circle: methylation call will be missed, because
fragments mass falls outside of spectral range of analysis; red diagonal line: approximate cleavage site; dotted line: combined methylation call duet o
overlapping peaksinspectrum.T-cleavage ismore informativethanC-cleavagewheninterrogatingCpGislandsduetoRNaseAdigestionaftereveryCpG
site in the C-cleavage reaction. (C) New schematic representation of DNA methylation data. Due to the speciﬁc fragmentation of a transcript, multiple
CpG sites can be present within one fragment. Also, fragments with identical masses will show overlapping peaks in the MALDI-TOF-MS spectrum,
resulting in a combined DNA methylation call. This new graphical representation of the DNA methylation incorporates all this information. The white
circlesrepresenttheCpGsitesthatareanalyzedintheMassCLEAVE
TMassay.ThecrossedgreycirclesrepresentCpGsitesthatwillbemissedintheassay,
and the red diagonal lines are the RNase A cleavage sites. The colored circles in the average view indicate the methylation calls given by the assay with the
dashed lines linking these calls back to the CpG site(s) within the interrogated sequence. In the detailed view, the relative abundance of unmethylated,
partially methylated, and fully methylated molecules is visualized as proportional bars for each fragment (white, gray and black bars, respectively). This
view allows an in-depth graphical comparison of samples at the highest resolution possible.
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The bisulphite reaction was performed on 2mg of DNA
for 16h at 558C under conditions as previously described
(19,25).
Clonal bisulphite sequencing forthe comparison withthe
MassCLEAVE
TM results
For the clonal genomic bisulphite sequencing, three inde-
pendent PCR reactions were performed on bisulphite-
treated DNA from the clinical samples and the products
were pooled, puriﬁed using the Wizard PCR DNA
puriﬁcation system, and cloned into the pGEM-T Easy
Vector (Promega). Approximately 12 individual clones
were sequenced from the pooled PCR reactions using the
Dye Terminator cycle sequencing kit with AmpliTaq
DNA polymerase, FS (Applied Biosystems) and the
automated 373A NA Sequencer (Applied Biosystems).
Primer sequences can be found in Supplementary Table 1.
To allow a comparison with the MassCLEAVE
TM assay,
the pooled PCR results were used in a re-PCR to enable a
T7-tagging of the PCR product prior to the transcription/
digestion and subsequent MALDI-TOF-MS analysis
described subsequently.
PCR-tagging andin vitro transcription
The target regions were ampliﬁed using the primer pairs
and annealing temperatures (Ta) described in
Supplementary Table 1. The PCR reactions were carried
out in a total volume of 5ml using 200nM forward and
reverse primer, 200mM dNTPs, 1.5mM MgCl2 and 0.35U
Platinum Taq DNA polymerase (Invitrogen) in 1  PCR
buﬀer without magnesium. The PCR ampliﬁcation was
performed as described in the Supplementary Table 1.
Unincorporated dNTPs were dephosphorylated by incu-
bation at 378C for 20min in the presence of 1.7mlH 2O
and 0.3U Shrimp Alkaline Phosphatase (Sequenom,
San Diego), followed by a heat-inactivation for 5min at
858C. Two microliters of this SAP-treated PCR mixture
were used as template in a 7ml transcription reaction,
containing 3.14mM DTT, 2.5mM dCTP, 1mM rUTP,
1mM rGTP, 1mM rATP, 20U T7R&DNA polymerase
(Epicentre, Madison, WI, USA) and 0.09mg/ml RNase A
in 0.64  T7 polymerase buﬀer (all reagents from
Sequenom, San Diego). Transcription and digestion
were performed simultaneously at 378C for 3h. After the
addition of 20mlH 2O, conditioning of the phosphate
backbone prior to MALDI-TOF MS was achieved by the
addition of 6mg CLEAN Resin (Sequenom, San Diego).
Further experimental details have been described
elsewhere (26).
MALDI-TOF-MS measurements
Twenty-two nanoliters of the cleavage reactions were
dispensed (nanodispenser) onto silicon chips preloaded
with matrix (SpectroCHIPs; Sequenom, San Diego). Mass
spectra were collected using a MassARRAY mass
spectrometer (Bruker–Sequenom). Spectra were analyzed
using proprietary peak picking and signal-to-noise
calculations.
Calculation of methylation ratios
Calculation of the DNA methylation levels was based on
the new formula described in this article, and performed
using the R-script ‘Analyze Sequenom Function’ (ASF):
see Supplementary Data. All statistical calculations were
carried out using either Stata 9 (StataCorp LP, Texas,
USA) or the free ‘R’ software package for statistical
computing (http://www.R-project.org).
RESULTS
In silico design and analysis of targetsequence
When designing a Sequenom MassCLEAVE
TM assay for
DNA methylation analysis, one of the ﬁrst steps is
selection of the genomic region of interest to interrogate
if the PCR ampliﬁed sequence is informative for MALDI-
TOFF analysis. Consideration of CpG density and speciﬁc
CpG sites required to be analyzed are critical in
determining the exact position of the PCR target
sequence. The MassCLEAVE
TM assay uses a speciﬁc
rNTP/dNTP nucleotide mixture together with T7
R&DNA polymerase, which allows incorporation of
both types of nucleotides. The subsequent RNase A
digestion results in a speciﬁc fragmentation pattern, as the
RNase A enzyme only cleaves 30 of every incorporated
rCTP and rUTP residue; the enzyme does not recognize
dCTP or dTTP. In the MassCLEAVE
TM kit, the
T-cleavage kit contains dCTP, rUTP, rGTP and rATP
Figure 1. Continued.
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rGTP and rATP resulting in a unique cleavage 30 of only
the rCTP or rUTP, respectively. For this reason, the
C-cleavage kit will not be as informative for CpG-rich
DNA, such as CpG islands, as every methylated or
unmethylated CpG site after bisulphite treatment is
cleaved by the RNase A enzyme and many small
uninformative fragments are generated. Therefore only
the T-cleavage kit was used in this study.
In silico RNase A digestion of a target region will not
only determine which PCR target sequence to amplify, but
also will identify which DNA strand will result in the most
informative CpG sites for methylation analysis. There a
number of reasons that CpG sites fail to be informative
and these include: (i) The MALDI-TOF-MS
MassCLEAVE
TM software has a default useable mass
window of 1500–7000Da and fragments that fall outside
this window will not be analyzed; (ii) Within one
fragment, multiple CpG sites may reside which will be
analyzed jointly, resulting in reduced resolution; (iii) In
rare cases, fragments may also have the exact same
nucleotide composition, and thus will overlap in the mass
spectrum. Since a bisulphite PCR is strand-speciﬁc (either
top or bottom strand is used as a template) (19), diﬀerent
fragmentation proﬁles will also be strand-speciﬁc from the
same genome sequence (Figure 1b). Ideally, all CpG sites
are analyzed individually and fall within the spectral range
of analysis, but in reality, a choice has to be made for the
most informative DNA strand to amplify and best
cleavage mixture to use. In the Supplementary Data, we
explain how an in silico fragmentation can be performed
using a new R-script we developed, called ‘Amplicon
Report Function’ (ARF). We have applied ARF to 20
well-known tumor suppressor genes, reviewed by Esteller,
2002 (27), to demonstrate the utility of this function in
assessing the target region prior to experimentation
(Supplementary Table 2). We also present a more accurate
schematic of the MassCLEAVE
TM fragmentation of a
target sequence that will aid substantially in interpretation
of the methylation results. The schematic incorporates the
relative position of each CpG site, which sites will be
missed (due to the limited spectral range of analysis),
which sites will be analyzed together in one fragment, and
which fragments will have overlapping masses. Moreover,
in the detailed view of the epigram, information is
presented on the number of CpG sites that are methylated
within each fragment (Figure 1c).
Precision andaccuracy of Sequenom DNA methylation
assay
To critically analyze the practical aspects of the
MassCLEAVE
TM procedure, we looked at the individual
steps of the protocol (Figure 1a). The two most important
measures of robustness of a quantitative measurement
procedure are precision (reproducibility) and accuracy
(true value). To address the precision and accuracy of the
MassCLEAVE
TM technology, and more speciﬁcally, of
the steps after PCR ampliﬁcation in the assay (Figure 1a),
we used cloned DNA fragments that had previously been
bisulphite converted, PCR ampliﬁed, cloned, sequenced
and veriﬁed as fully methylated or unmethylated
sequences, as templates to amplify PCR control products
from the CpG island promoters of Engrailed-1 (EN1),
secretin receptor (SCTR) and inhibin beta B (INHBB)
(23). Known ratios of the fully methylated and unmethy-
lated PCR products were mixed (0, 5, 10, 25, 50, 75, 90, 95
and 100%) and either (i) analyzed immediately in a T7
transcription-RNase A digestion reaction, followed by a
MALDI-TOF-MS analysis (referred to as direct analysis,
hereafter) or (ii) analyzed following an extra PCR step
(referred to as PCR+analysis, hereafter). These latter
PCR+analysis samples more closely resemble the
Sequenom MassCLEAVE
TM procedure since, after
bisulphite conversion, a PCR step is always needed for
the ampliﬁcation and T7 promoter tagging. All reactions
were performed in ﬁve replicates and analyzed individu-
ally. The results for EN1 are presented here; all data for
SCTR and INHBB are given as Supplementary Data ﬁles.
Precision in the detection of DNA methylation levels. In
both the direct analysis and the PCR+analysis experi-
ment, most cleaved fragments obtained from the three
individual gene targets (EN1, SCTR, INHBB) reveal
remarkably consistent methylation levels, with standard
errors not larger than 0.175 (median 0.011; Figure 2a and
Supplementary Figures 2 and 3). The methylation calls
with the lowest precision appear to be for fragments with a
mass below  1700Da (fragments left of the dashed
vertical line in each panel of Figure 2a), indicating that
these data points should be disregarded and the lower
boundary of the spectral range settings should be
increased from the default value (1500Da) to 1700Da.
Accuracy of the detection of DNA methylation levels in the
direct analysis. We then investigated the accuracy of
DNA methylation calls of fragments with a mass over
1700Da. In general, the DNA methylation levels detected
in the direct analysis revealed a very high correlation with
the input methylation levels for all three targets (Figure 2b
and Supplementary Figures 2 and 3; EN1: r
2=0.98;
SCTR: r
2=0.99; INHBB: r
2>0.99). However, we
observed a small but consistent bias when analyzing
fully unmethylated (0%) or fully methylated (100%) input
samples; the MassCLEAVE
TM technology consistently
measured a small (2.5–5%) increase or decrease in
methylation levels, respectively, in all the amplicons
analyzed. When analyzing the methylation calls separately
for all fragments, again we observed the least accurate
data for fragments below 1700Da, which could show
either unjustly high or low methylation levels (Figure 2a
and Supplementary Figures 2 and 3). Therefore, for both
precision and accuracy reasons, the lower threshold of the
spectral range should be increased to  1700Da.
Accuracy bias introduced by the PCR amplification
step. All bisulphite-based DNA methylation analysis
methods, including clonal sequencing and
MassCLEAVE
TM, require a PCR ampliﬁcation step
following the bisulphite conversion of DNA. We therefore
tested whether an accuracy bias is introduced at this step
by performing a PCR on the methylated/unmethylated
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Figure 2. Accuracy and precision of MassCLEAVE
TM DNA methylation detection in EN1 CpG island. The reproducibility and quantitation of diﬀerent
CpG methylation levels were assessed using MassCLEAVE
TM technology (A) We measured the DNA methylation calls according to the
MassCLEAVE
TM technology, but using ASF (Supplementary Data). Known input ratios of completely methylated and unmethylated DNA fragments
(referred to as 0, 5, 10, 25, 50, 75, 90 or 100% methylated input DNA; panels from upper left to lower right, respectively) were either analyzed immediately
in a T7 transcription-RNase A digestion reaction, followed by a MALDI-TOF MS analysis (direct analysis, gray bars), or analyzed following an extra
PCR step (PCR+analysis, black bars). For each panel, the methylation calls are arranged per fragment in an increasing mass order (x-axis) and the
measured methylation ratios (y-axis) are given as means+SEM of ﬁve replicate measurements. The dotted vertical line indicates the 1700Da threshold,
and the horizontal dotted lines represent the input methylation levels. (B) Accuracy of DNA methylation calls by MassCLEAVE
TM and PCR-induced
bias. The left panel shows the mean DNA methylation calls of fragments with a mass over 1700Da (y-axis) plotted against the input levels (x-axis),
revealing a high correlation between input and output levels. The right panel shows the diﬀerence between the assay output and the known input (error)
versus the input DNA methylation levels, revealing a small but consistent bias. The data for the direct analysis is plotted as a grey line and the data for
PCR+analysis is shown as a dashed black line. Data are given as means+SEM of ﬁve replicate measurements. Similar accuracy and precision data for
SCTR and INHBB CpG islands are given as Supplementary Data ﬁles.
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digestion and MALDI-TOF-MS analysis
(PCR+analysis). For all three amplicons, at very low
and high methylation input levels we found a bias in
methylation levels towards the under-represented copy
(Figure 2b and Supplementary Figures 2 and 3), a similar
bias was reported previously (17); input samples with
methylation 40.25 were always given an elevated call,
whereas input samples with methylation 50.5 were given
a deﬂated call. The bias was consistently more pronounced
at high methylation levels (maximum bias  0.09,  0.20
and  0.20 for EN1, SCTR and INHBB, respectively) than
at low methylation levels (maximum bias +0.05, +0.09,
+0.09 for EN1, SCTR and INHBB, respectively). Since
this bias is not observed in the direct analysis, this eﬀect is
most likely introduced by the PCR ampliﬁcation step.
Next, we determined how instructive the assay was in
detecting small diﬀerences in input methylation levels,
based on the results of the PCR+analysis experiment.
In the cases where we could compare a 5% diﬀerence in
input methylation levels (0–5%, 5–10%, 90–95% and
95–100%), we were able to detect a signiﬁcant diﬀerence
in methylation calls in 77% of the situations (95 out of 124
fragments interrogated). A 10% input diﬀerence was
detected signiﬁcantly in 92% of the cases (57 out of 62
fragments; input levels of 0–10% and 90–100%; two-tailed
Wilcoxon rank-sum test, P<0.05).
Minimal amount oftemplate fortranscription and
MassCLEAVE
TManalysis
We determined how robust the MassCLEAVE
TM tech-
nology is by measuring the minimal amount of PCR
product necessary for a successful DNA methylation
analysis. We prepared for all three amplicons a dilution
series of a 50% methylated PCR mixture ranging
from 80 down to 2.5nM and used these as template in
the T7 transcription-RNase A digestion step and
subsequent MALDI-TOF-MS analysis (Figure 3a and
Supplementary Figures 4 and 5). At the lowest concentra-
tion tested (2.5nM), a considerable number of replicates
failed to generate detectable fragments with distinctive
signal-to-noise ratios in the spectrum (Figure 3b and
Supplementary Figures 4 and 5). However, even at this
concentration, the methylation calls that were made were
reasonably accurate (maximum error=0.086, median
0.047; Figure 3c and Supplementary Figures 4 and 5).
It should here be noted that a reduction of concentration
of the EN1 template resulted in a small increase in average
methylation level, whereas the reverse correlation was
observed for the INHBB amplicon. Thus, variations in
PCR yield should be kept to a minimum and useful mass
spectrums will be obtained with at least  5nM of
template.
Variability dueto bisulphite conversion and PCR
We next determined how much variability in DNA
methylation levels would be introduced by the bisulphite
treatmentofgenomicDNA(gDNA)andbythesubsequent
PCR ampliﬁcation of this single-stranded bisulphite-
treated DNA. A mixture of 25% enzymatically methylated
gDNA in a background of unmethylated DNA was
bisulphite converted and CpG island containing regions
of the EN1, SCTR and INHBB genes were PCR-ampliﬁed
in triplicate. This entire procedure was repeated three times
to be able to interrogate the contribution of bisulphite
treatment to the variability in the measurements. We ﬁrst
analyzed the variability generated by the PCR step on the
same bisulphite-treated genomic DNA by assessing three
diﬀerent PCR ampliﬁcations. After calculation of the
methylation calls for the diﬀerent fragments, the standard
errors for three PCR replicates on the same bisulphite-
treated gDNA ranged from 0.02 to 0.09 for EN1 (median
0.04); from 0.00 to 0.07 for SCTR (median 0.02); and from
0.07 to 0.21 for INHBB (median 0.11; Figure 4a and
Supplementary Figures 6 and 7). To assess the variability
due to the bisulphite step, we averaged the methylation
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Figure 3. Template dilution test for transcription and subsequent
MALDI-TOF analysis. The minimal amount of PCR template required
for accurate quantitation of DNA methylation was determined.
(A) A twofold dilution series was prepared from T7-tagged PCR
ampliﬁcations of EN1 CpG island (50/50% mixture of fully unmethy-
lated and fully methylated PCR product), ranging from 80 to 2.5 nM,
and 5 ml of each dilution was visualized on an agarose gel. Adjacent
marker lanes contain 500ng pBR322 digested with HinFI. (B) Two
microliters of the dilution series was used in the transcription-RNase A
digestion reaction and subjected to MALDI-TOF MS analysis, in ﬁve
technical replicates. The ratio of detected versus expected fragments
with CpG sites was determined in all spectra and are presented as
individual bars for each analysis. (C) The average methylation calls
ratios calculated from the detected peaks in the spectra are shown as
means+SEM. The dotted horizontal line represents the actual
methylation level used as input. Similar template dilution studies for
SCTR and INHBB CpG island regions are given as Supplementary
Data ﬁles.
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treated gDNA for each fragment to remove the inﬂuence of
the PCR in the call and then compared these methylation
calls for the three diﬀerent bisulphite treatments.
Surprisingly, the standard errors of the methylation calls
for three diﬀerent bisulphite treatments were smaller than
those caused by the PCR, and ranged from 0.02 to 0.05 for
EN1 (median 0.03), from 0.01 to 0.02 for SCTR (median
0.02) and from 0.01 to 0.04 for INHBB (median 0.03;
Figure 4b and Supplementary Figures 6 and 7), indicating
that the PCR step introduces more variability in the
methylation calls than the bisulphite treatment.
SYBR Green incorporation facilitates high-throughput
analysis ofPCR success
A crucial step in the Sequenom DNA methylation
analysis is the PCR ampliﬁcation, as a successful PCR is
likely to result in a good MALDI-TOF-MS spectrum and
thus in an accurate determination of the DNA methyla-
tion status of the fragments. The current recommendation
(28) for conﬁrmation of a successful PCR is an agarose
gel-based analysis. However, the MALDI-TOF-MS ana-
lysis uses chips that analyze 384 samples in one assay,
which demands for a rapid screening technique to address
the PCR success. We, therefore, determined if SYBR
Green-based melt curve analysis would be preferable as a
high-throughput screen for PCR success and whether
SYBR Green interferes with the downstream transcription
and RNase A digestion and subsequent MALDI-TOF-
MS analysis. We found that the melt-curve analysis after
the PCR ampliﬁcation step allowed a rapid analysis of the
presence or absence of PCR products and at the same time
gave global information on the methylation status of the
samples based on the melting temperature of the product
(Figure 5a and Supplementary Figures 8 and 9).
We tested the inﬂuence of SYBR Green on the
transcription reaction, RNase A cleavage and subsequent
MALDI-TOF-MS analysis. To this end, we added SYBR
Green to PCR products derived from mixtures
of enzymatically methylated gDNA in a background of
unmethylated DNA (mixes of 0, 25 and 100% methylated
gDNA) and compared the results with samples lacking
SYBR Green. We found no indication that the addition of
SYBR Green inﬂuenced the methylation calling
(Figure 5b and Supplementary Figures 8 and 9).
All three target regions revealed similar DNA methylation
levels regardless of the presence or absence of SYBR
Green; statistical analysis of the methylation calls for
each fragment with or without SYBR Green did not
reveal any signiﬁcant diﬀerences (Wilcoxon rank-sum;
P<0.05). Therefore, we conclude that addition of SYBR
Green to the PCR does not signiﬁcantly aﬀect the
MassCLEAVE
TM assay and permits a high-throughput
validation of PCR success prior to mass spectrometry.
Comparison of MassCLEAVE
TMwithclonal bisulphite
sequencing
A critical question that has not as yet been addressed is
how accurate the MassCLEAVE
TM procedure is in
quantifying DNA methylation levels when compared to
clonal bisulphite sequencing analysis. To examine this, we
performed a clonal bisulphite analysis of PCR fragments
derived from the three CpG island target regions (EN1,
SCTR and INHBB) from six clinical samples; three
colorectal tumor and matched normal samples).
Bisulphite-converted DNA was PCR ampliﬁed in tripli-
cate and pooled, and the pooled PCR products were either
cloned and 10 clones sequence veriﬁed or the pooled PCR
products were T7-PCR-tagged and analyzed using the
MassCLEAVE
TM protocol (Figure 6). To enable a
comparison between the results of both techniques, we
converted the clonal sequencing data into the Sequenom
output format per fragment. Although the results are not
completely identical, there appears to be considerable
agreement between DNA methylation levels detected by
clonal sequencing and MassCLEAVE
TM assay. The
discrepancy in the results is most likely caused by the
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Figure 4. Variability in DNA methylation quantitation. Methylation
variability due to bisulphite conversion or PCR ampliﬁcation was
evaluated. (A) In three independent experiments, a mixture of 25%
enzymatically methylated gDNA and 75% blood gDNA (generally
unmethylated) was bisulphite treated in triplicate and EN1 CpG island
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present within one fragments, whereas the equals to sign (=) is indicative
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calls shown in this graph is caused by PCR ampliﬁcation of bisulphite-
treated single-stranded DNA. (B) To be able to interrogate the variability
introduced by the bisulphite conversion, we calculated the average
methylation calls of the triplicate PCR reactions on the same bisulphite-
treated gDNA, and used these values to graph the DNA methylation calls
per fragment obtained from three independent bisulphite conversions.
Similar variability studies for SCTR and INHBB CpG island regions are
given as Supplementary Data ﬁles.
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analysis, which may not be fully representative for the
total pool of molecules present. On the other hand, the
clonal sequencing data gives more detailed information at
the level of single CpG sites and at the level of actual
distribution of the methylation signals over individual
molecules (i.e. cells).
Analysis ofregions forallelic-specific DNA methylation by
MALDI-TOF-MS
Allelic-speciﬁc DNA methylation, where one allele is
methylated and the other allele is unmethylated commonly
occurs in normal cells such as in genes on the
X-chromsome (X-inactivation) and in diﬀerentially
methylated regions (DMRs) located near imprinted
genes. Diﬀerential methylation of one allele and not the
other can also occur in aging and in cancer where a CpG
island promoter is aberrantly methylated and the gene
inactivated while the active allele remains unmethylated.
The standard technique to analyze allelic-speciﬁc or
diﬀerential methylation is by clonal bisulphite sequencing
in which two distinct populations can be detected that are
similar in size (approximately equal number of fully
methylated and unmethylated sequences). We adapted the
MassCLEAVE
TM assay design and analysis to allow the
detection of two pools of DNA methylation states in one
sample (Figure 7a). In the MassCLEAVE
TM spectrum,
this causes a depletion of peaks representing partially
methylated fragments. By selecting a transcript fragmen-
tation pattern that is enriched in fragments containing
more than one CpG site this unique peak pattern can be
visualized most clearly. For example, in an imprinted
region only two peaks in the spectrum should be
representing each fragment: one for the fully methylated
allele and one for the fully unmethylated allele. The
presence of additional peaks would indicate a loss of
imprinting (Figure 7a). Although the results from such a
MassCLEAVE
TM-based imprinting assay diﬀer from
traditional clonal bisulphite sequencing results, in that
information is obtained for only small genomic fragments
at a time (Figure 7b), the combined results of the
MassCLEAVE
TM assay still allows a high-throughput
analysis of the imprinting status of larger genomic regions.
MALDI-TOF-MS for analysis of polymorphisms linked to
allele-specific DNA methylation status
Polymorphisms in the DNA sequence analyzed can be a
signiﬁcant problem in the MassCLEAVE
TM assay. The
presence of SNPs in the target region may cause a mass
shift in the spectrum or even a diﬀerent fragmentation
pattern, which can easily lead to a misinterpretation of the
results. The Epityper
TM software does not allow the
interrogation of SNPs and can only analyze the fragmen-
tation pattern of a single sequence entered per spectrum.
However, if a SNP is causing an altered peak pattern after
bisulphate treatment and ampliﬁcation, it can also be used
for a high-throughput analysis of the allelic distribution of
this SNP in your sample cohort and even be exploited for
the analysis of the allele-speciﬁc methylation status.
To illustrate this, we interrogated the fragmentation
pattern of the imprinted control region of the GNAS
cluster on chromosome 20q13.32 using the
MassCLEAVE
TM assay. When we analyzed the spectrum,
we observed an unusual peak distribution for one of the
transcript fragments (Figure 7c). After sequencing valida-
tion, we discovered this distribution to be caused by the
presence of a novel genomic SNP in the region (an A/T
substitution at position chr20:56,859,403[-]; deposited in
the SNP database as ss71641550). This A to T substitution
changed the transcription fragment (in antisense orienta-
tion) CRCCAAACAACCT into ACRCCAAACCT,
resulting in a 329Da mass increase for this fragment.
After detailed analysis of the MassCLEAVE
TM results of
192 Australian Caucasian individuals, the T allele
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Figure 5. SYBR Green melt curve analysis to determine PCR success.
SYBR Green PCR melt curve analysis and its compatibility with the
MassCLEAVE
TM assay was assessed. (A) The use of SYBR Green in
the PCR reaction enables a rapid screening for a successful ampliﬁca-
tion. Here, typical results of a completely methylated (red line), a
completely unmethylated (green lines) and a no template control (blue
line) PCR of EN1 CpG island are shown. Rapid screening using SYBR
Green PCR melt curve analysis also yields information on the global
methylation state of the region interrogated (i.e. a temperature shift in
the position of the peak in the melt curve, indicated by the two-headed
arrow). (B) A comparison of a MassCLEAVE
TM analysis with or
without SYBR Green for EN1 CpG island (solid blue line or dashed
black line, respectively) revealed similar results, indicating that SYBR
Green does not inﬂuence the methylation calling in the assay. Similar
studies for SCTR and INHBB CpG island regions are given as
Supplementary Data ﬁles.
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of Australian Caucasian individuals (32 out of 384 alleles
tested). As a second example, we interrogated in silico the
fragmentation pattern of the imprinted control region of
the H19/IGF2 cluster on chromosome 11 using our
R-script ARF for all the SNPs known within the ampliﬁed
region. We found a diﬀerential fragmentation pattern
between the alleles of the SNP rs10732516 (A/G).
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Figure 6. Comparison of DNA methylation quantitation by MassCLEAVE
TM and clonal bisulphite sequencing. Three samples of colorectal tumor and
matched normal tissue were analyzed for the DNA methylation status of the CpG islands of EN1, SCTR or INHBB. In each graph panel, the colored line
(either red for tumor or green for matched normal) represents the results obtained from the MassCLEAVE
TM assay (triplicate assays). The dashed black
line is derived from the clonal bisulphite sequencing results shown under each graph; the binary data (either methylated or unmethylated) of 10–11 clones
was combined according to the fragmentation pattern in the MassCLEAVE
TM assay. The CpG sites corresponding to fragments are indicated by the
connecting lines under the graphs (gray lines for adjacent sites and pink lines for non-adjacent sites). The DNA methylation levels appear similar in both
assays, indicating the robustness of both techniques. Asterisks indicate MassCLEAVE fragments with a mass below 1700Da. White and black circles
represent unmethylated and methylated CpG sites, respectively, and ‘A’ (red) depicts a polymorphism for rs2244213. The MassCLEAVE data for INHBB
in patient 9-tumor have not been determined.
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region in a number of healthy control samples using the
MassCLEAVE
TM assay indeed revealed the presence or
absence of these peaks in the spectrum (Figure 7d).
Moreover, since we analyzed an imprinted region in both
examples, we were able to directly deduce the DNA
methylation status of the neighboring CpG site(s), which
allows the identiﬁcation of the methylated and unmethy-
lated allele (either paternal or maternal). Therefore we
conclude that the MassCLEAVE
TM assay can also be
exploited for SNP discovery, rapid SNP genotyping and
quantitative allele-speciﬁc methylation analysis.
DISCUSSION
Over the last decade, the rapidly expanding interest in the
involvement of DNA methylation in developmental
mechanisms and human diseases has highlighted the
need for an accurate, quantitative and high-throughput
assay for DNA methylation screening. Recently, a
MassCLEAVE
TM assay has been developed using a
MALDI-TOF-MS-based analysis of base-speciﬁc
fragmentation patterns after bisulphite conversion (20).
This assay provides the potential for fast, quantitative
screening of detailed methylation patterns using
automated procedures in large patient cohorts. In this
article, we have critically assessed this procedure and
present signiﬁcant improvements of the MassCLEAVE
TM
assay and experimental design that now enables this
technology to be exploited for detailed analysis of
genome methylation patterns including allelic-speciﬁc
methylation.
One of the ﬁrst critical steps in the MassCLEAVE
TM
assay is in the design and location of the target sequence to
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Figure 7. Analysis of allele-speciﬁc methylation levels. Allele-speciﬁc methylation levels of GNAS and H19/IGF2 imprinted regions using
MassCLEAVE
TM assay was determined. (A) Hypothetical MALDI-TOF spectrum section for a diﬀerentially methylated imprinted region. The three
CpG sites present in this fragment can give rise to four diﬀerent peaks, depending on the methylation status of each individual CpG site. In an
imprinted region, one allele is completely methylated and the other allele completely unmethylated, therefore only two peaks of equal signal-to-noise
ratio should be present, representing both alleles. (B) Theoretical comparison of the DNA methylation analysis of an imprinted region using either
clonal bisulphite sequencing or MassCLEAVE
TM approach (for an explanation of schematic assay, see Figure 1c). Both assays can discriminate
between imprinted and non-imprinted regions. (C) Example of SNP discovery using the MassCLEAVE
TM assay. An unexpected peak distribution
was obtained in the MALDI-TOF-MS analysis of the imprinted control region of the GNAS cluster on chromosome 20 (chr20:56,859,
080-56,859,449). Analysis of the composition of the novel peak revealed the presence of a novel SNP (deposited as ss71641550 [A/T]). The
fragmentation of this region associated the polymorphism with the methylation status of the neighboring CpG site, allowing an allele-speciﬁc
methylation call for this site (the black or white circles represent methylated or unmethylated CpG sites, respectively). (D) Example of simultaneous
SNP genotyping and analysis of the allele-speciﬁc methylation status. Four diﬀerent genomic samples were analyzed for the imprinting status of the
imprinted control region of the H19/IGF2 cluster (chr11:1,977,509-1,977,914) using the MassCLEAVE
TM assay and revealed the SNP status for
rs10732516. Since the fragment containing this polymorphism also contains one or three CpG sites, the methylation status associated with the
neighboring CpG sites could be deduced simultaneously. Note that the peaks for the A allele of rs10732516 overlap with the peaks of another
fragment (CpG7) resulting in increased peak heights.
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that will be informative for accurate methylation analysis.
To enable a prior assessment of each target sequence, we
developed a new formula, called ‘the Amplicon Report
Function’ (ARF) that calculates the correct average
methylation levels of fragments that contain more than
one CpG site, using a weighting of the partially
methylated peaks in the MALDI-TOF spectrum. ARF
enables a comprehensive in silico analysis of the fragmen-
tation pattern of any target sequence to analyze how
informative a region will be and whether it is recom-
mended to design the assay from either the top or bottom
strand of the DNA, as this will yield diﬀerent fragmenta-
tion patterns. Diﬀerent questions will require diﬀerent
sequence options: for example, it is preferential to have as
few CpG sites per fragment in the methylation analysis of
CpG islands, whereas more than one CpG site per
fragment is optimal for analysis of imprinted regions to
determine allelic-speciﬁc methylation.
In optimization of the MassCLEAVE
TM assay, we
replaced the time-consuming agarose gel analysis of PCR
success with a rapid SYBR Green PCR melt curve
analysis. PCR melt curve analysis permits a high-
throughput screen for PCR ampliﬁcation without
any further sample manipulations; this is essential in any
high-throughput assay. Furthermore, we have shown that
the inclusion of SYBR Green in the assay did not aﬀect
the accuracy or precision of the assay, and the success
of a MassCLEAVE
TM analysis of DNA methylation is
only limited by the success of the PCR ampliﬁcation.
We assessed the precision and accuracy of the
MassCLEAVE
TM technology and found that for
fragments below  1700Da the calibration is not optimal,
as peak position is not always called correctly. This is
compounded by the fact that fragments below this mass
commonly contain only a small number of nucleotides
(<6 nucleotides), thereby increasing the likelihood of
overlapping fragments with the same composition.
We, therefore, recommend that the lower boundary of
the spectral range be increased from the default value of
1500–1700Da to ensure more precise and accurate
methylation calls.
We next performed a detailed analysis of all steps in the
MassCLEAVE
TM assay, to determine which steps of the
procedure introduced the most variability in the measure-
ment of CpG methylation and found that it was the PCR
ampliﬁcation of the bisulphite-treated genomic DNA.
This is similar to previous ﬁndings (29,30), but it is in
contrast to what has been published very recently (31),
where most of the variability in the measurement was
attributed to the bisulphite treatment. However, in that
study the analysis of the variability was not separated into
the individual assay steps, hence most variability was
observed in the earliest steps of the protocol.
We recommend that in the MassCLEAVE
TM assay, the
PCR step should be replicated at least three times to
obtain reliable results and that each PCR fragment is
analyzed separately or pooled prior to analysis. In cases
where very large cohorts need to be analyzed, and the
inclusion of this many replicates is not an option, it is
recommended to at least pool multiple PCR reactions
prior to downstream methylation analysis to minimize this
PCR-induced variability. In the results presented here, we
were able to consistently detect a 5% diﬀerence in input
DNA methylation level with the transcription/digestion
and MALDI-TOF-MS analysis in 77% of the situations
tested. We, therefore, conclude that this technique will
generally allow the detection of methylation diﬀerence
down to  5%.
Since the MassCLEAVE
TM assay is designed for high-
throughput quantitative methylation assessment across
genomic regions it is critical that it is comparable to the
current gold standard method in methylation analysis,
clonal PCR bisulphite sequencing. As a comparison has
not previously been reported we undertook a direct
comparison of clonal PCR bisulphite sequencing and the
MassCLEAVE
TM methylation assay on colorectal tumor
and matched normal tissue samples. We obtained highly
comparable results in levels of DNA methylation at
informative CpG sites, with the caveat that clonal analysis
permits interrogation of each individual CpG site in the
regions interrogated, whereas the MassCLEAVE
TM assay
only examines the average methylation data per cleavage
fragment. However, the MassCLEAVE
TM assay is highly
quantitative, whereas the clonal sequencing analysis is
easily biased by the limitation in the number of clones
analyzed. The MassCLEAVE
TM assay is clearly favorable
in a high-throughput experiment as it is less time
consuming and more cost-eﬀective.
Other high-throughput methods for quantitative DNA
methylation analysis have recently been described includ-
ing pyrosequencing (32) and a bead-based analysis from
Illumina (33). Pyrosequencing is a real-time DNA
sequencing by synthesis method that can be used after
bisulphite treatment for direct quantitative methylation
analysis (14). The sensitivity of the method is similar to
MALDI-TOF mass spectrometry (5%), but the main
limitation of this method is the length of the sequence read
and thereby the number of CpG sites that can be analyzed
in one sequencing reaction (17,32). Bead-based array
methylation analysis can be performed using multiplexing
and is useful for DNA methylation of multiple genes
simultaneously in large populations. This method can be
sensitive down to less than 5% for some CpG sites but is
also limiting in assessment of contiguous CpG sites (33).
One of the major advantages of the new adaptations we
have implemented is the analysis of allelic-speciﬁc
methylation such as imprinted genomic regions and
diﬀerential methylation in cancer samples. Normally,
diﬀerentially methylated imprinted regions show a bimo-
dal and allele-speciﬁc methylation status; one allele is
methylated and inactive, and the other is active and
unmethylated. Changes in this pattern can cause imprint-
ing diseases, such as the Beckwith–Wiedemann syndrome
or the Prader–Willi syndrome (9). While bisulphite clonal
sequencing (34) and some PCR and pyrosequencing-based
approaches have already been reported for allelic-speciﬁc
methylation analysis (35–37), allele-speciﬁc loss of methy-
lation can also be visualized in the MassCLEAVE
TM
assay using a fragmentation pattern that is speciﬁcally
selected for fragments containing multiple CpG sites.
Similar to pyrosequencing (37), the MassCLEAVE
TM
e119 Nucleic Acids Research, 2007, Vol. 35, No. 18 PAGE 12 OF14assay permits a rapid and quantitative method of allele-
speciﬁc DNA methylation analysis. Our R-script ARF
allows a rapid selection of the optimal assay conditions
when interrogating imprinted regions. Allelic-speciﬁc
methylation can be further addressed if a sequence
variation or SNP is present in the region interrogated.
When the SNP is located in a fragment with one or more
CpG sites, the allele-speciﬁc methylation status (and
inheritance) of these sites can be addressed. However, in
general, special care always needs to be taken for the
presence of potential SNPs when using the Mass
CLEAVE
TM assay. Since no actual sequence information
will be obtained from a MALDI-TOF spectrum, no direct
validated warning can be given for a spectrum aﬀected by
the SNP and thus a misinterpretation can easily occur.
However, with the initiation of the HapMap project and
manyotherSNPgenotypinganalyses,newinformationwill
continue to be compiled on potential SNPs that lie within
interrogated regions, and the R-script ARF we developed
can address whether a certain SNP can cause a change in
the (expected) spectrum.
In conclusion, we have made critical improvements to
MassCLEAVE
TM technology, enabling easy and informa-
tive assay designs that result in accurate and quantitative
analyses of CpG methylation. We have shown that the
MassCLEAVE
TM assay is robust, with DNA methylation
proﬁles comparable to clonal bisulphite sequencing, but
unlike bisulphite sequencing, the method is quantitative
and more suitable for high-throughput analyses of large
sample cohorts. Our adaptations to the assay permit for
the ﬁrst time high-throughput methylation genomic
proﬁling that provides information on both heterogeneous
and allele-speciﬁc DNA methylation levels that is critical if
we are to understand DNA methylation dynamics in
normal and diseased states.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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